ADI will be run by Mr. Douglas MacLellan who continuing, Many exciting opportunities exist for ADI and its own investors. Onko-Sure can identify and/or monitor for 14 various kinds of cancers, including lung, stomach, colorectal, liver, and breasts cancer which according to the World Health Organization, causes the most cancer deaths every year. Our intention is to consider Onko-Sure and ADI to a level our shareholders haven’t experienced before. With the exception of heart disease, cancer causes even more deaths than any various other condition in the global globe. Based on the World Health Company , cancer is quickly becoming the leading cause of death worldwide and likely to overtake heart disease by 2010. Onko-Sure has been approved by the united states FDA for the monitoring of colorectal cancer and by Wellness Canada as a lung tumor screen and cancers monitoring tool.Sinnige, M.D., Ph.D., Dirk J. Richel, M.D., Ph.D., Emile E. Voest, M.D., Ph.D., Jeroen R. Dijkstra, B.Sc., Marianne E.Sc., Ninja F. Antonini, M.Sc., Linda Mol, M.Sc., Johan H.J.M. Van Krieken, M.D., Ph.D., Otilia Dalesio, M.Sc., and Cornelis J.A. Punt, M.D., Ph.D.: Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer Fluoropyrimidines , irinotecan, and oxaliplatin will be the standard cytotoxic medicines used in treating metastatic colorectal cancers.1,2 The mix of capecitabine and oxaliplatin is comparable to the combination of fluorouracil and oxaliplatin in efficacy and safety.3,4 Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor , 5-7 coupled with fluoropyrimidine-based chemotherapy is currently the standard first-series treatment for metastatic colorectal tumor.